Companies.
Introduction
Tumor cell migration, invasiveness and metastasis formation are important therapeutic targets in oncology drug development. The hepatocyte growth factor (HGF), also known as scatter factor, and its receptor c-Met, play an important role in physiological processes such as embryological development, wound healing, tissue regeneration, angiogenesis, cell growth, local invasion and morphogenetic differentiation (1) . In physiological and pathophysiological situations HGF is primarily produced by fibroblast like cells, whereas c-Met is expressed by epithelial cells. Aberrant expression of c-Met is involved in tumor progression (2, 3) . Activating c-Met mutations have been identified in hereditary and sporadic papillary kidney cancer and gastric carcinomas, suggesting a potential causal role for c-Met activation in tumorigenesis (4, 5) . Moreover c-Met amplification is a well-known event in non-small cell lung cancer especially important in resistance to EGFR inhibition (6) . In a small subset of glioblastoma multiforme patients activating c-Met mutations have been reported and activation of the HGF-c-Met axis seems to play a role in resistance to therapy (7) . Therefore, inhibiting the activity of cMet is a relevant objective in anti-cancer drug development. If 0 out of 3 patients experienced DLT during the first 21 day treatment cycle, dose escalation could be pursued according to protocol. If 1 out of 3 patients experienced DLT during the first treatment cycle, up to 3 additional patients were to be treated at that dose level. The MTD was defined as the highest dose level at which fewer than 2 out of 6 patients experienced DLT.
Pharmacokinetics (PK):
Blood samples were taken at pre-specified times (see Supplemental methods) and analyzed quantitatively for JNJ-38877605 and the N-desmethyl metabolite, M2. For both compounds, Cmax, time to Cmax (tmax), elimination half life time (t1/2), area under the plasma concentration curve (AUC) and terminal elimination rate were calculated.
Toxicology studies in the model organisms:
Toxicology studies were performed according to ICH Topic S9. Nonclinical Evaluation Human metabolites should be covered in the toxicology species in order to assess compound and metabolite related toxicity during the 1-month GLP toxicology study.
Based on metabolite patterns in hepatocytes all human metabolites were present in rat and dog with the exception of an N-glucuronide, which is considered to be non-toxic.
Therefore, rat and dog were identified as suitable species to test toxicity.
Following the observation of renal toxicity in the clinical study we chose rabbits because of the presence of the glucuronide of the desmethylmetabolite (M10) in rabbit and man, only. A 1-month non-GLP toxicology study of JNJ-38877605 was performed in the male rabbit and histopathological evaluation of the kidney was performed as well as all other standard tissue testing and sampling. In order to find possibilities to circumvent renal toxicity, various intermittent dosing schedules were explored (see table 1 for the dosing regimen and total weekly dose).
Research. Isoenzymes involved in the formation of the metabolites:
Isoenzyme identification was performed with liver subcellular fractions. Isoenzymes involved in the metabolism of JNJ-38877605 were determined based on structural characteristics and after incubation with specific inhibitors of cytochrome P-450 and aldehyde oxidase (9) .
Histopathological evaluation:
Rabbit kidneys were fixed by formalin immersion, then processed routinely: trimming, embedding, sectioning at 3-5 µm, staining with hematoxylin and eosin (HE) and examined under bright field. Additional frozen sections of kidney were prepared and counterstained with either methylene blue or Von Kossa (to detect mineralization). They were examined under bright field and polarization microscopy.
Identification of the crystal structures in the kidneys:
Kidney crystals detected under polarization microscopy were observed and analyzed in situ using Raman microscopy. Thereafter, they were harvested and analyzed with LC-MS.
Prevention of renal toxicity:
A mechanistic study was performed to investigate the potential protective effect of probenecid on renal toxicity. Probenecid is known as a competitive inhibitor of organic acid transport in the kidney and other organs (10) 
Results
Toxicity in the phase I, first in human study of JNJ-38877605 A total of 5 subjects were enrolled in the first cohort of 60 mg OD. All subjects experienced a rapid, though asymptomatic Grade 1 serum creatinine (SCr) increase; in 4 patients this occurred as early as 2-3 days after the start of treatment, whereas 1 patient completed 4 weeks of treatment prior to SCr increase. In all cases treatment was interrupted. In 1 patient a re-challenge with JNJ-38877605 at the same dose was pursued after a 3-day interruption of therapy and subsequent normalization of SCr; this patient again experienced a grade 1 SCr increase after which treatment was permanently discontinued. All subjects recovered from their SCr increase after permanent treatment discontinuation. Cystatin C and blood urea nitrogen showed a comparable pattern to SCr, whereas calculated creatinine clearance decreased accordingly in 4 patients ( Figure 1A /B).
To explore potential safe dose levels, an amendment was pursued allowing for dose levels of 10-40 mg OD to be explored. While 10 and 20 mg OD appeared to be safe with no indication of renal toxicity, at 40 mg OD again a rapid though asymptomatic grade 1 SCr increase was observed in 2/3 patients. It was then decided to discontinue further enrolment. During this part of the study glomerular filtration rate determination by Based on a previous inter-species comparison of its metabolism, it was hypothesized that the renal toxicity of JNJ-38877605 that already occurred at sub-therapeutic doses, could possibly be explained by species specific metabolism. After incubation of JNJ-38877605 with liver fractions and identification of the metabolites with LC/MS-MS, several metabolites were observed. The major metabolic pathways in humans were demethylation, leading to M2, that was further metabolized to M5/M6 by hydroxylation of the quinoline moiety and to M10 by glucuronidation. JNJ-38877605 was also hydroxylated at the quinoline moiety to M1/M3. (Figure 2, Supplemental table 3) . A comparative metabolism study in hepatocytes of rat, dog, rabbit and man showed a species-dependent formation of M10 (major in man and rabbit) and M11 (minor) (Supplemental figure 1). We therefore hypothesized that M10 could play a role in the observed clinical renal toxicity and subsequently selected rabbit as a toxicity model.
Renal effects after JNJ-38877605 administration during 1 month in rabbits
After total weekly intake of 200, 300 and 350 mg/kg/week for 1 month, creatinine clearance and several other chemistry parameters started changing. At necropsy (Table   1) , rabbit kidneys showed increased weights (groups 3-6) and appeared pale (groups 4-6). Histopathological evaluation showed an extensive and prominent degeneration with inflammation, congestion, fibrosis, regeneration, and granular and acicular clefts sometimes surrounded by giant cells (Table 1 ; Figure 3B -D). In frozen sections examined under polarization microscopy, these clefts proved to be bi-refringent crystalline granules and spicules ( Figure 3E/F) . Some of the observed changes, in particular the kidney weight changes and the crystal accumulation, were still present after a 1-month recovery period(Supplemental table 4), with a moderate increase in urea nitrogen and a slight increase in creatinine.
As renal crystal formation was probably related to the formation of insoluble metabolites of JNJ-38877605 in the urine, we explored the potential protective effect of coadministration of probenecid. As probenecid is a competitive inhibitor of organic acid transport in the kidney and other organs, we hypothesized that it could block the renal transport of JNJ-38877605 and its metabolites. In a 7-day rabbit study, probenecid co- UV reference spectra allowed for the conclusion that both proposed structures contain a 2-hydroxyquinoline chromophore, with proposed structure 1 relating to JNJ-38877605 metabolites M5, M6 and proposed structure 2 relating to metabolites M1, M3. Additional experiments showed that the M5 metabolite displayed poor solubility at with a maximum concentration of 2-3 µg/ml solute over a range of pH.
We next performed mass balance studies in rats, dogs and rabbits showing that the excretion of JNJ-38877605 and its metabolites occurs partly through the kidney and rabbits and humans pre-dominantly excrete M3 and M5 in the urine. In rabbit urinary excretion was more important compared to rat and dog (data not shown). Plasma profiling showed a much lower abundance of M3 and M5 in rat and dog compared to rabbit and human (Table 2 ). These data suggested that plasma levels of M3 and M5
and their renal excretion play a critical role in the explanation of the renal findings.
Identification of the isoenzymes involved
Identification of the isoenzymes involved in the metabolism of JNJ38877605 is based on studies with specific inhibitors in liver microsomes and supernatant fractions. M3 is the most important metabolite formed after incubation of JNJ-38877605 with human liver supernatant and is almost undetectable in human liver microsomes (Table 3a) . This suggests that M3 is primarily formed by cytosolic enzymes. This is further corroborated by the fact that quercetin completely inhibited the formation of M3 in 12000xg fractions (Table 3b) . Quercetin is a potent inhibitor of molybdenum hydroxylases like xanthine oxidase and aldehyde oxidase. Aldehyde oxidase is known to oxidize quinoline moieties, therefore most probably aldehyde oxidase and not xanthine oxidase is involved in the metabolism of JNJ-38877605. In addition, 1-aminobenzotriazole, a general cytochrome P-450 inhibitor, barely inhibits the M3 formation which is in line with the assumptions above (Table 3b ). Cytochrome P-450 3A4 is clearly involved in the formation of the other metabolites. M5, the equivalent of M3 but originated from the demethylated JNJ-38877605 (M2) was not formed in microsomes or 12000xg. Based on the structural similarity with M3, it is assumed that it is also formed by aldehyde oxidase.
Research. 
Discussion
In this first-in-human phase I study with the c-Met tyrosine kinase inhibitor JNJ-38877605 renal toxicity, hampering continuation of treatment, was observed after a short timeframe and at virtually all, even sub-therapeutic dose levels. Based upon the at that time available results from preclinical studies performed in mice, rats and dogs, this renal toxicity had not been foreseen. Extensive additional pre-clinical research therefore was initiated. Based on the subsequent analysis of metabolism data, the rabbit was subsequently identified as a relevant toxicity model. In this model we were able to recognize aldehyde oxidase-dependent and species-specific formation of insoluble metabolites that induced renal toxicity through precipitation of insoluble crystals in the renal tubules.
In the clinical study, although strongly and repeatedly considered, it was decided not to perform renal biopsies in any of the patients, and therefore the presence of such crystals in any of our patients could not be confirmed. This decision was based upon the clinical and ethical consideration that patients in this study had only asymptomatic Grade 1 serum creatinine (SCr) increases. Unfortunately, we were not able to come up with a viable strategy to circumvent renal toxicity in the subsequently performed rabbit studies, and therefore it was decided that further clinical development of JNJ-38877605 had to be stopped.
With regard to the observed clinical toxicity of JNJ-38877605, it is intriguing that seemingly comparable observations were made In a phase I study with SGX523, another ATP competitive small molecule c-Met inhibitor (11) . At doses exceeding 80 mg renal toxicity consisting of early rises in BUN and creatinine and obstructive nephropathy were observed. SGX523 equally showed a clean toxicity profile in rat and dog. SGX523 induced renal toxicity was considered probably related to the formation of two insoluble metabolites which were not formed in rat and dog. Subsequent studies performed in monkeys revealed the formation of crystals within renal tubules. The major urine metabolites in monkey were 2-quinolinone-SGX523 and the desmethyl metabolite The nephrotoxic metabolites could be detected in all hepatocytes cultures thus confounding the early signs of potential species specific generation. One hypothesis would be that they are formed by enzyme activity in the kidney. This hypothesis is corroborated by the lack of efficacy of probenecid. It is reported that the proximal, distal and collecting ducts of the kidney express aldehyde oxidase (13) . Species specific aldehyde oxidase activity may contribute to the observed differences: in humans its activity is relatively high compared to rats and dogs (14) . More conventional renal protective strategies such as hyper-hydration and furosemide co-administration were considered less suitable as we aimed for chronic administration of JNJ-38877605. In 
related small molecule c-Met inhibitor did induce a comparable spectrum of renal toxicity, which also prompted investigators to interrupt further clinical development (11, 12) . These data underpin our observation that quinoline-containing chemical structures can be metabolized in a species-specific manner to form nephrotoxic poorly soluble metabolites explaining the observed renal toxicity of SGX523 and JNJ-38877605.
Revealing rabbit as an appropriate model system allowed us to explore potential strategies to circumvent the renal toxicity. Unfortunately, neither alternative scheduling of JNJ-38877605 nor probenecid co-administration proved to be a successful strategy in preventing renal toxicity. A potential strategy we have not explored is inhibiting aldehyde oxidase itself. A list of 239 drugs inhibiting aldehyde oxidase has been reported (19) .
Raloxifene is one of these inhibitors of aldehyde oxidase (IC 50 value of 0.0029 μM), and therefore, combining JNJ-38877605 with raloxifene could have been considered another preventive strategy to try to circumvent renal toxicity caused by JNJ-38877605.
In conclusion, JNJ-38877605 is an orally available, nanomolar active (IC50 4.7 nM for cMet Kinase in vitro) and highly selective c-Met ATP competitive kinase inhibitor whose clinical activity was hampered by unexpected renal toxicity. Combined clinical and correlative preclinical studies suggest that this renal toxicity is caused by the formation of species specific insoluble metabolites that specifically occurs in rabbits and humans.
These observations preclude further clinical development of JNJ-38877605.
Research. Species  Metabolites  UD  M1  M2  M3  M4  M5  M6  M7  M10  Rat  136  64  57  15  6  1466  Dog  31  55  40  575  Rabbit  6388  778  603  2259 1780  395  822 22836  Man  3  387  208  2  111 The metabolites of JNJ-38877605 were determined in urine/faeces of rat, dog and rabbit and in urine of man. Animals were dosed with 3H-JNJ-38877605 at 2.5 mg/kg in rat, 2.5 mg/kg in dog and 100 mg/kg in rabbit. Humans were dosed at 60 mg. JNJ-38877605 and its metabolites in plasma were expressed as ngeq/ml. Metabolites were measured at about Cmax ranging between 1 and 4h depending on the species. UD=unchanged drug or JNJ-38877605 
